Setting standards in participant rights and research integrity

Research conducted by NEOMED using human participants is overseen by the Institutional Review Board (IRB).

The primary purpose of the NEOMED IRB is to facilitate the review, approval, modification and disapproval of human subject research protocols, while ensuring the rights and welfare of human subjects are protected while participating in research. The NEOMED IRB is registered to review research governed by the Office of Human Research Protections (OHRP).

NEOMED has partnered with Advarra, a commercial entity outside IRB, to provide review and oversight of research governed by the Federal Drug Administration (FDA).

The IRB process at NEOMED is based on rules and regulations for federally funded research, primarily the Code of Federal Regulation (45 CFR 46) and supporting materials such as the Belmont Report.

Board

Application Review and Meeting Dates

Applications received for projects which meet the exempt or expedited review categories will be reviewed by the IRB chair or other members in the order received and are subject to the reviewer’s availability and workload.  Please expect up to 10 working days to receive an initial written review of your project.

Projects determined to be above minimal risk will require review by the convened IRB committee .  Contact the IRB coordinator at researchcompliance@380cebbe0d.nxcli.io for the next scheduled meeting date.   Please note all materials requiring full board review must be submitted two weeks prior to the full board meeting date.  Submit all materials electronically to the researchcompliance@380cebbe0d.nxcli.io.

The IRB Submission and Review Process